Volume 6, Issue 21 (1-2016)                   NCMBJ 2016, 6(21): 99-106 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salehipour M, Zaker Bostanabad S, Rezaee S, Hashemi-Shahraki A. Antimicrobial susceptibility of clinical isolates of Nocardia in Iran. NCMBJ 2016; 6 (21) :99-106
URL: http://ncmbjpiau.ir/article-1-768-en.html
Pasteur Institute of Iran, Tehran, Iran , abdolrazaghh@gmail.com
Abstract:   (9147 Views)

Aim and background:The aim of this multicenter study was to determine the antibiotic susceptibility of clinically isolated Nocardia species. 

Material and methods:One hundred twenty-seven patients with nocardiosis were randomly selected from 5 provinces of Iran. Molecular diagnosis of Nocardia species was performed using 16S rRNA sequencing. Antimicrobial susceptibility testing was performed following the Clinical and Laboratory Standards Institute recommendations.

Results:Thirty-five N. cyriacigeorgica, 30 N. asteroides, 26 N. farcinica, 12 N. otitidiscaviarum, and 10 N. abscessus cultures were studied. All isolates were susceptible to linezolid. All isolates of N. cyriacigeorgica, N. asteroides, N. abscessus, and N. otitidiscaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica isolates were resistant to this drug. All N. otitidiscaviarum isolates were highly resistant to imipenem, but N. cyriacigeorgica, N. asteroides, N. farcinica, and N. abscessus were only moderate resistant.

Conclusion:The susceptibility patterns vary with different species of Nocardia. Resistance to trimethoprim-sulfamethoxazole in Iran is low and this drug should be first line therapy, unless drug susceptibility testing shows resistance. Linezolid also covers Nocardia well and could be a second line agent.

Full-Text [PDF 304 kb]   (2257 Downloads)    
Type of Study: Research Article | Subject: Microbiology
Received: 2016/01/21 | Accepted: 2016/01/21 | Published: 2016/01/21

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb